Ofatumumab launch date?

When did ofatumumab first launch (market approval vs first commercial availability)?

Ofatumumab’s first launch in the U.S. was in 2009, when the FDA approved the drug for chronic lymphocytic leukemia (CLL) under the brand name Arzerra. The approval date was October 26, 2009 [1].

Which ofatumumab product are people usually referring to (Arzerra vs other indications)?

Most searches for “ofatumumab launch date” refer to Arzerra (ofatumumab), the anti-CD20 monoclonal antibody that was first approved for CLL in 2009 [1]. Later approvals expanded or refined its use, but the launch date typically points to that initial 2009 FDA action [1].

Are there different “launch dates” by country or regulatory body?

Yes. A drug’s “launch date” can mean different things depending on the country and how you measure it:
- Regulatory approval date (what the FDA/EMA marks as approval)
- First commercial shipment/market entry (when it became widely available)
The provided source here is the FDA approval date for the initial U.S. launch context [1].

Patent/exclusivity timing: where to check the timeline

For additional commercial timing context tied to brand history and patent filings, DrugPatentWatch.com is a useful reference point (including dates and related patent information) [2].

Sources

[1] https://www.drugs.com/history/ofatumumab.html
[2] https://www.drugpatentwatch.com/